Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 421 to 435 of 694 results for end of life care

  1. Bortezomib for previously untreated mantle cell lymphoma (TA370)

    Evidence-based recommendations on bortezomib (Velcade) for untreated mantle cell lymphoma in adults.

  2. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments (TA862)

    Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults.

  3. Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)

    Evidence-based recommendations on beta interferons (Avonex, Betaferon, Extavia, Rebif) and glatiramer acetate (Copaxone) for treating multiple sclerosis in adults.

  4. Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor (TA1062)

    Evidence-based recommendations on erdafitinib (Balversa) for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor in adults.

  5. Ectopic pregnancy and miscarriage: diagnosis and initial management (NG126)

    This guideline covers diagnosing and managing ectopic pregnancy and miscarriage in women with complications, such as pain and bleeding, in early pregnancy (that is, up to 13 completed weeks of pregnancy). It aims to improve how early pregnancy loss is diagnosed, and the support women are given, to limit the psychological impact of their loss.

  6. Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over (TA1039)

    Evidence-based recommendations on selpercatinib (Retsevmo) for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over.

  7. Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)

    Evidence-based recommendations on enzalutamide (Xtandi) for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.

  8. NICE glossary

    The NICE glossary provides brief definitions and explanations of terms used on the website. The terms describe how NICE works and how its guidance is produced.

  9. Entecavir for the treatment of chronic hepatitis B (TA153)

    Evidence-based recommendations on entecavir for treating chronic hepatitis B in adults.

  10. Thyroid cancer: assessment and management (NG230)

    This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with thyroid cancer.

  11. Aortic remodelling hybrid stent insertion during surgical repair of an acute type A aortic dissection (IPG733)

    Evidence-based recommendations on aortic remodelling hybrid stent insertion for acute type A aortic dissection. This involves inserting a stent with material sewed on one end into part of the aorta.

  12. Human growth hormone (somatropin) in adults with growth hormone deficiency (TA64)

    Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth hormone deficiency in adults.

  13. Dupilumab for treating severe asthma with type 2 inflammation (TA751)

    Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over.

  14. CentriMag for heart failure (MIB92)

    NICE has developed a medtech innovation briefing (MIB) on CentriMag for heart failure .

  15. Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer (TA903)

    Evidence-based recommendations on darolutamide (Nubeqa) with androgen deprivation therapy and docetaxel for hormone-sensitive metastatic prostate cancer in adults.